Welcome to our dedicated page for Solventum SEC filings (Ticker: SOLV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Solventum's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Solventum's regulatory disclosures and financial reporting.
ALBAN CARLOS reported acquisition or exercise transactions in this Form 4 filing.
Solventum Corp director Carlos Alban received a grant of 3,300 Restricted Stock Units (RSUs). Each RSU represents the right to receive 1 share of Solventum common stock upon settlement, so this award covers 3,300 underlying shares. The RSUs were granted at no cash cost and will fully vest on May 15, 2027, if he continues serving through that date. Following this grant, Alban holds 3,300 RSUs directly, reflecting a routine, compensation-related equity award rather than an open-market share purchase or sale.
COX CARRIE SMITH reported acquisition or exercise transactions in this Form 4 filing.
Solventum Corp director Carrie Smith Cox received a grant of 4,848 Restricted Stock Units, each representing one share of common stock upon settlement. These RSUs were awarded at no cash cost and will fully vest on May 15, 2027, if her service continues through that date.
Solventum Corp director Susan D. DeVore received a grant of 3,300 Restricted Stock Units (RSUs) that convert into the same number of common shares upon settlement. The award was given at no cash cost to her and represents equity-based compensation rather than an open-market purchase.
The RSUs are scheduled to fully vest on May 15, 2027, provided she continues to serve through that date. Following this grant, her reported holdings in RSUs tied to common stock total 3,300 units, aligning her compensation more closely with future company performance.
Edwards Shirley Ann reported acquisition or exercise transactions in this Form 4 filing.
Solventum Corp director Shirley Ann Edwards received a grant of 3,300 Restricted Stock Units as equity compensation. Each RSU represents a right to receive one share of common stock upon settlement. The RSUs will fully vest on May 15, 2027, if she remains in service through that date.
EISENBERG GLENN A reported acquisition or exercise transactions in this Form 4 filing.
Solventum Corp director Glenn A. Eisenberg received a grant of 3,300 Restricted Stock Units, each representing a contingent right to one share of common stock upon settlement. These RSUs vest in full on May 15, 2027, subject to continued service, leaving him with 3,300 derivative units reported after this award.
Harris Bernard A Jr reported acquisition or exercise transactions in this Form 4 filing.
Solventum Corp director Harris Bernard A Jr received a grant of 3,300 Restricted Stock Units, each representing a right to receive one share of common stock upon settlement. These RSUs were awarded at no cash cost to him and will fully vest on May 15, 2027, if he continues in service through that date.
MAY KAREN J reported acquisition or exercise transactions in this Form 4 filing.
Solventum Corp director Karen J. May received a grant of 3,300 Restricted Stock Units (RSUs). These RSUs give her the right to receive 3,300 shares of Solventum common stock upon settlement. The award fully vests on May 15, 2027, subject to her continued service with the company, and represents her full reported RSU holdings after this grant.
Mily Elizabeth reported acquisition or exercise transactions in this Form 4 filing.
Solventum Corp director Mily Elizabeth received a grant of 3,300 Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of Solventum common stock upon settlement. The RSUs will fully vest on May 15, 2027, if she continues serving through that date.
Following this equity award, she holds 3,300 RSUs directly. This is a compensation-related grant rather than an open-market share purchase or sale.
WEILAND JOHN H reported acquisition or exercise transactions in this Form 4 filing.
Solventum Corp director John H. Weiland received a grant of 3,300 Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive 1 share of Solventum common stock upon settlement. The RSUs will fully vest on May 15, 2027, if he continues serving through that date.
Wendell Amy McBride reported acquisition or exercise transactions in this Form 4 filing.
Solventum Corp director Wendell Amy McBride received a grant of 3,300 restricted stock units as equity compensation. Each RSU represents a contingent right to receive 1 share of Solventum common stock upon settlement. The award vests in full on May 15, 2027, subject to continued service. Following this grant, McBride holds 3,300 RSUs directly.